121 related articles for article (PubMed ID: 38154513)
1. Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Patients With Inoperable Esophageal Squamous Cell Carcinoma Undergoing Curative-Intent Concurrent Chemoradiotherapy.
Chang CL; Lin KC; Chen WM; Shia BC; Wu SY
J Thorac Oncol; 2024 May; 19(5):818-828. PubMed ID: 38154513
[TBL] [Abstract][Full Text] [Related]
2. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
4. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
5. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Lertbutsayanukul C; Kitpanit S; Kannarunimit D; Chakkabat C; Oonsiri S; Thephamongkhol K; Puataweepong P; Katanyoo K; Sukhaboon J; Tovanabut C; Chongsathientham S; Treeratsapanich P; Soonthornrak J; Prayongrat A
Trials; 2022 Oct; 23(1):897. PubMed ID: 36273186
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
Chang CL; Tsai HC; Lin WC; Chang JH; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Radiother Oncol; 2017 Oct; 125(1):73-79. PubMed ID: 28923576
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
Ren XJ; Wang L; Han C; Liu LL
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
[No Abstract] [Full Text] [Related]
9. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
[TBL] [Abstract][Full Text] [Related]
10. Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study.
Fan XW; Wang HB; Mao JF; Li L; Wu KL
Cancer Med; 2020 Apr; 9(8):2812-2819. PubMed ID: 32100452
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.
Blanchard P; Garden AS; Gunn GB; Rosenthal DI; Morrison WH; Hernandez M; Crutison J; Lee JJ; Ye R; Fuller CD; Mohamed AS; Hutcheson KA; Holliday EB; Thaker NG; Sturgis EM; Kies MS; Zhu XR; Mohan R; Frank SJ
Radiother Oncol; 2016 Jul; 120(1):48-55. PubMed ID: 27342249
[TBL] [Abstract][Full Text] [Related]
12. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
Pao TH; Chang WL; Chiang NJ; Chang JS; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
Radiat Oncol; 2020 Sep; 15(1):221. PubMed ID: 32962730
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
15. Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Cortiula F; Hendriks LEL; Wijsman R; Houben R; Steens M; Debakker S; Canters R; Trovò M; Sijtsema NM; Niezink AGH; Unipan M; Urban S; Michelotti A; Dursun S; Bootsma G; Hattu D; Nuyttens JJ; Moretti E; Taasti VT; De Ruysscher D
Radiother Oncol; 2024 Jan; 190():110019. PubMed ID: 38000689
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: A population-based propensity-score-matched analysis.
Li CC; Chen CY; Chien CR
Medicine (Baltimore); 2018 Jun; 97(22):e10928. PubMed ID: 29851829
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma.
Li M; Fu C; Zhang W; Huang W; Wang Z; Zhou T; Lin H; Li B
Br J Radiol; 2016; 89(1060):20150476. PubMed ID: 26891913
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study.
Zhang W; Xie Q; Zhu B; Wang X; He L; Zhang Y
Medicine (Baltimore); 2022 Apr; 101(16):e29166. PubMed ID: 35482986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
